|View printer-friendly version|
|ChromaDex to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019|
Investor Conference Call:
ChromaDex management will host an investor conference call to discuss the fourth quarter results and provide a general business update on Thurs., Mar. 7, at 4:30 p.m. ET.
Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:
Date: Thurs., Mar. 7, 2019
A replay of the conference call will be available after 7:30 p.m. ET.
Toll-free replay number: 1-855-859-2056
ChromaDex Corp. is a consumer-facing biotechnology company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about
ChromaDex Media Contact:
ChromaDex Investor Relations Contact: